Assembly Actions - Lowercase Senate Actions - UPPERCASE |
|
---|---|
Dec 22, 2021 | signed chap.720 |
Dec 10, 2021 | delivered to governor |
Jun 03, 2021 | returned to assembly passed senate 3rd reading cal.1294 substituted for s649a |
May 24, 2021 | referred to finance delivered to senate passed assembly |
May 13, 2021 | advanced to third reading cal.347 |
May 11, 2021 | reported |
Feb 02, 2021 | reported referred to ways and means |
Jan 14, 2021 | referred to health |
assembly Bill A2030
Signed By GovernorSponsored By
ROSENTHAL L
Current Bill Status - Signed by Governor
- Introduced
- In Committee
- On Floor Calendar
- Passed Senate
- Passed Assembly
- Delivered to Governor
- Signed by Governor
Your Voice
Actions
Votes
Co-Sponsors
Dan Quart
Diana Richardson
Robert C. Carroll
David Weprin
A2030 (ACTIVE) - Details
A2030 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 2030 2021-2022 Regular Sessions I N A S S E M B L Y January 14, 2021 ___________ Introduced by M. of A. L. ROSENTHAL, QUART, RICHARDSON, CARROLL, WEPRIN, SIMON, GOTTFRIED, HEVESI -- read once and referred to the Committee on Health AN ACT to amend the social services law and the public health law, in relation to medication for the treatment of substance use disorders THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (gg) to read as follows: (GG) ALL BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFES- SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER. SUCH MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO ANY PRIOR AUTHORI- ZATION MANDATE. § 2. Subdivision 26-b of section 364-j of the social services law, as added by section 4 of part B of chapter 69 of the laws of 2016, is amended to read as follows: 26-b. Managed care providers shall not require prior authorization for [an initial or renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid addiction unless the prescription is for a non-preferred or non-formu- lary form of the drug or as otherwise required by section 1927(k)(6) of the Social Security Act] ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFESSIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER. § 3. Subdivision 10 of section 273 of the public health law, as amended by section 7 of part GG of chapter 56 of the laws of 2020, is amended to read as follows: EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.